Қазақ ұлттық қыздар педагогикалық университеті / Казахский национальный женский педагогический университет

Постоянный URI для этого сообществаhttps://cris.qyzpu.kz/handle/123456789/1

Просмотр

Фильтры

20263

Настройки

Тема: search.filters.subject.bactericidal activity

Результаты поиска

Показано: 1 - 3 из 3
  • Загрузка...
    Изображение-миниатюра
    Некоторые метрики заблокированы вашими 
    настройками согласия
    Тип записи:Публикация,
    In Vitro Measurement of Genotoxicity of Antimicrobial Dextrin–Polyvinyl Alcohol–Iodine Complex
    (Multidisciplinary Digital Publishing Institute, 2026-07-20)
    Tamara Bukeyeva
    ;
    Seitzhan Turganbay
    ;
    Ardak B. Jumagaziyeva
    ;
    Zhanar A. Iskakbayeva
    ;
    Saltanat Jumabayeva
    Iodine-based antimicrobial materials are widely considered for biomedical applications due to their broad-spectrum antimicrobial activity; however, their potential genotoxicity requires systematic evaluation prior to clinical use. The aim of this study was to assess the genotoxic potential of a dextrin–polyvinyl alcohol–iodine (D/PVA/I-1) complex in accordance with OECD guidelines. Genotoxicity was evaluated in vitro using two complementary assays: the mammalian cell micronucleus test (OECD TG 487) in L5178Y TK+/− cells and the bacterial reverse mutation assay (Ames test, OECD TG 471) using Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and Escherichia coli WP2 uvrA, both in the presence and absence of metabolic activation (S9). In the micronucleus assay, no statistically significant increase in micronucleus frequency was observed at concentrations ranging from 0.039 to 0.625 mg/mL compared with the negative control. In the Ames test, no increase in revertant colony numbers was detected in any tested bacterial strain at concentrations up to 1250 μg/plate. At higher concentrations, pronounced cytotoxic and bactericidal effects were observed without evidence of mutagenic activity. Overall, the results demonstrate that the D/PVA/I-1 complex does not exhibit genotoxic or mutagenic potential under the tested in vitro conditions, indicating a favorable genetic safety profile and supporting further preclinical evaluation for potential biomedical applications.
  • Загрузка...
    Изображение-миниатюра
    Некоторые метрики заблокированы вашими 
    настройками согласия
    Тип записи:Публикация,
    DEVELOPMENT, PHARMACEUTICAL EVALUATION, AND ASSESSMENT OF THE BACTERICIDAL ACTIVITY OF THE KC-250 TABLET FORMULATION AGAINST CLINICALLY SIGNIFICANT MICROORGANISMS
    (2026-08-21)
    Daniil Shepilov
    ;
    Zhassur Taganov
    ;
    Ardak B. Jumagaziyeva
    ;
    Sabina T. Kenesheva
    ;
    Saltanat Jumabayeva
    Introduction: Conversion of iodine-containing complexes into solid dosage forms requires adequate tablet strength while preserving disintegration, release, and antimicrobial activity. This study aimed to develop a directly compressed KC-250 tablet formulation, evaluate its pharmaceutical quality, and determine its bactericidal activity against clinically significant bacteria. Methods: Tablets containing 60 mg of KC-250 at a target mass of 500 mg were prepared using MicroceLac® 100, povidone K30, and magnesium stearate. Compression forces of 3.24 and 6.96 kN were compared by friability and disintegration testing. The selected formulation was evaluated for pharmacopoeial quality attributes. Bactericidal activity against eight reference, resistant, and clinical bacterial strains was determined in triplicate by broth serial dilution followed by agar subculture. Results: Increasing compression force from 3.24 to 6.96 kN reduced friability from 0.81% to 0.21%, while disintegration increased from 1.62 to 4.62 min. Tablets produced at 6.96 kN had friability of 0.20%, a disintegration time of 4 min 54 s, a KC-250 content of 63.05 mg/tablet, and dissolution of 102.95% within 45 min. All evaluated attributes complied with the predefined acceptance criteria. Minimum bactericidal concentrations were 60 mg/mL for the tested Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa strains and 30 mg/mL for Enterococcus faecalis and Enterococcus faecium. Discussion: Compression at 6.96 kN provided the most appropriate balance between mechanical resistance and rapid disintegration without restricting KC-250 release. The retained bactericidal activity indicates that tablet formulation did not eliminate the antimicrobial function of KC-250 and supports further development of the selected MicroceLac® 100– povidone K30 matrix.
  • Загрузка...
    Изображение-миниатюра
    Некоторые метрики заблокированы вашими 
    настройками согласия
    Тип записи:Публикация,
    D/PVA/I-1 as an Antibiotic Adjuvant: In Vitro Synergy and Membrane Permeabilization in MDR Bacteria
    (Multidisciplinary Digital Publishing Institute, 2026-08-17)
    Ardak B. Jumagaziyeva
    ;
    Seitzhan Turganbay
    ;
    Anar Seisembekova
    ;
    Daniil Shepilov
    ;
    Zhanar A. Iskakbayeva
    Background: Antimicrobial resistance (AMR) is among the most pressing challenges in modern infectious medicine, driving progressive failure of standard antibacterial therapy and rising mortality from infections caused by multidrug-resistant (MDR) pathogens. Antibiotic potentiation through adjuvant compounds capable of restoring the activity of existing drugs represents a promising strategy to overcome resistance without developing fundamentally new antibacterial molecules. This study aimed to evaluate the antibiotic-potentiating activity of a dextrin/polyvinyl alcohol/iodine complex (D/PVA/I-1), developed at the Scientific Center for Anti-Infectious Drugs JSC (Almaty, Kazakhstan), against clinically relevant MDR reference strains. Methods: Nine reference strains, Staphylococcus aureus (ATCC 33591, BAA-39), Escherichia coli (ATCC BAA-196, BAA-2523), Klebsiella pneumoniae (ATCC BAA-2524, 700603), Acinetobacter baumannii (ATCC BAA-1790), Streptococcus pneumoniae (ATCC BAA-660), and Haemophilus influenzae (ATCC 33930), and two clinical isolates, P. aeruginosa SCAID PHRX1-2019 and E. coli SCAID WND1-2021, were tested. Antibiotic-potentiating activity was assessed by checkerboard assay with calculation of the fractional inhibitory concentration index (FICI); bactericidal kinetics were evaluated by time-kill analysis. The effect of D/PVA/I-1 on cytoplasmic membrane permeability was investigated using a crystal violet uptake assay. Results: Of 45 D/PVA/I-1–antibiotic combinations tested across nine antibiotics, synergy (FICI ≤ 0.5) was demonstrated in 44.4% of cases, partial synergy in 48.9%, and additive effects in 6.7%; no antagonistic interactions were detected. The most pronounced potentiating effect occurred against Gram-positive pathogens, particularly MRSA strains (66.7% synergistic combinations). Time-kill analysis confirmed suppression of the regrowth phenotype characteristic of MDR strains under monotherapy and restoration of bactericidal activity against antibiotics to which strains exhibited intrinsic resistance. D/PVA/I-1 induced a dose- and time-dependent increase in membrane permeability in both Gram-positive and Gram-negative organisms. Conclusions: D/PVA/I-1 is an effective broad-spectrum antibiotic potentiator and represents a promising basis for combination therapy regimens against MDR infections.